| Literature DB >> 31860298 |
Hao Chen1, Shanshan Deng1, Yuxi Wang2, Najah Albadari1, Gyanendra Kumar3, Dejian Ma1, Weimin Li2, Stephen W White3, Duane D Miller1, Wei Li1.
Abstract
We recently reported the crystal structure of tubulin in complex with a colchicine binding site inhibitor (CBSI), ABI-231, having 2-aryl-4-benzoyl-imidazole (ABI). Based on this and additional crystal structures, here we report the structure-activity relationship study of a novel series of pyridine analogues of ABI-231, with compound 4v being the most potent one (average IC50 ∼ 1.8 nM) against a panel of cancer cell lines. We determined the crystal structures of another potent CBSI ABI-274 and 4v in complex with tubulin and confirmed their direct binding at the colchicine site. 4v inhibited tubulin polymerization, strongly suppressed A375 melanoma tumor growth, induced tumor necrosis, disrupted tumor angiogenesis, and led to tumor cell apoptosis in vivo. Collectively, these studies suggest that 4v represents a promising new generation of tubulin inhibitors.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31860298 DOI: 10.1021/acs.jmedchem.9b01815
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446